Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
3actual
Sites
1
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The decision is based on strategic deprioritization and is not related to any safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-23 | actual | When the study began enrolling |
| Primary completion | 2026-02-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-26 | actual | The whole study's end, after follow-up |
| First posted | 2025-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rare Diseases
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
Primary outcomes
what the primary-completion date above is the date OFBaseline demographics and clinical characteristics
measured At inclusion
Pre-inclusion relapse history
measured From NMOSD diagnosis to inclusion (retrospective baseline)
Pre-inclusion NMOSD-related hospitalizations
measured From NMOSD diagnosis to inclusion (retrospective baseline)
Time from first symptoms to NMOSD diagnosis
measured From first NMOSD symptoms to date of diagnosis (retrospective baseline)
Prior misdiagnoses profile
measured From first NMOSD symptoms to confirmed NMOSD diagnosis (retrospective baseline)
AQP4-IgG testing method
measured At time of NMOSD diagnostic workup (retrospective baseline)
MRI brain T2-hyperintense lesion count change
measured Baseline (≤12 months pre-inclusion) and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Optic nerve MRI findings
measured Baseline (≤12 months pre-inclusion) and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Spinal cord MRI lesion metrics
measured Baseline (≤12 months pre-inclusion) and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Relapse prevention therapy patterns
measured From NMOSD diagnosis to inclusion and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Acute relapse treatment modalities
measured From NMOSD diagnosis to inclusion and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Concomitant medications
measured From NMOSD diagnosis to inclusion and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed